Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian A Rowe

Showing results (1-10 of 92) with videos related to

Pageof 10
Sort By:
Journal of Hepatology|April 6, 2023
Understanding the risks and benefits of policy action in NAFLDIan A Rowe
Clinical Liver Disease|April 18, 2019
Understanding the benefits and risks in donor liver allocationIan A Rowe
The Lancet. Gastroenterology & Hepatology|February 7, 2020
Decision making for liver biopsy in NASH, not so FAST?Ian A Rowe
Seminars in Liver Disease|September 9, 2020
Histological Endpoints for Nonalcoholic Steatohepatitis Trials: Lights and ShadowsIan A Rowe
Nature Reviews. Gastroenterology & Hepatology|November 30, 2017
The devotion to surrogate outcomes in drug development for liver diseaseIan A Rowe
Journal of Hepatology|November 28, 2025
Optimal strategies to prevent disease progression and clinical events in MASLDIan A Rowe
Hepatology (Baltimore, Md.)|September 3, 2010
Sorafenib therapy in patients with hepatocellular carcinoma before liver transplantationIan A Rowe
Alimentary Pharmacology & Therapeutics|November 12, 2019
Editorial: evolving histological assessment of NASHIan A Rowe
Digestive Diseases (Basel, Switzerland)|May 4, 2017
Lessons from Epidemiology: The Burden of Liver DiseaseIan A Rowe
Frontline Gastroenterology|August 26, 2017
Opportunities to improve surveillance for hepatocellular carcinoma in the UKIan A Rowe
Pageof 10

Showing results (1-10 of 92) with videos related to

Sort By:
Pageof 10
Journal of Hepatology|April 6, 2023
Understanding the risks and benefits of policy action in NAFLDIan A Rowe
Clinical Liver Disease|April 18, 2019
Understanding the benefits and risks in donor liver allocationIan A Rowe
The Lancet. Gastroenterology & Hepatology|February 7, 2020
Decision making for liver biopsy in NASH, not so FAST?Ian A Rowe
Seminars in Liver Disease|September 9, 2020
Histological Endpoints for Nonalcoholic Steatohepatitis Trials: Lights and ShadowsIan A Rowe
Nature Reviews. Gastroenterology & Hepatology|November 30, 2017
The devotion to surrogate outcomes in drug development for liver diseaseIan A Rowe
Journal of Hepatology|November 28, 2025
Optimal strategies to prevent disease progression and clinical events in MASLDIan A Rowe
Hepatology (Baltimore, Md.)|September 3, 2010
Sorafenib therapy in patients with hepatocellular carcinoma before liver transplantationIan A Rowe
Alimentary Pharmacology & Therapeutics|November 12, 2019
Editorial: evolving histological assessment of NASHIan A Rowe
Digestive Diseases (Basel, Switzerland)|May 4, 2017
Lessons from Epidemiology: The Burden of Liver DiseaseIan A Rowe
Frontline Gastroenterology|August 26, 2017
Opportunities to improve surveillance for hepatocellular carcinoma in the UKIan A Rowe
Pageof 10